In patients with non-small cell lung cancer (NSCLC) with an EGFR-activating mutation, treatment with a tyrosine kinase inhibitor (TKI) controls the disease in only 20% of cases, and fewer than one in five patients achieve a survival of more than five years. The goal of the PRECISION-PREDICT project (HDH, BPI France) is to develop predictive models based on clinical and radiomic data from PET imaging to better anticipate the response to targeted therapies.
To achieve this, we rely on data collected from nine Unicancer centers identified via ConSoRe: Institut Curie, Centre Oscar Lambret, Centre François Baclesse, Institut Bergonié, Institut du Cancer de Montpellier, Institut Paoli-Calmettes, Centre Jean Perrin, Centre Léon Bérard, and Centre Georges-François Leclerc.
People involved in the lab : Hervé Brisse, Toulsie Ramtohul, Marie Luporsi, Fanny Orlhac (co-responsible), Irène Buvat (co-responsible).